PE
ADMA icon

Point72 Europe’s ADMA Biologics ADMA Stock Holding History

Point72 Europe’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$62.4K Buy
+4,256
New +$73K ﹤0.01% 341

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SHCM
Sachem Head Capital Management New York $4.15B AUM 48.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Point72 Europe's ADMA Position: Q3 2025 in Review

Point72 Europe opened a new position in ADMA Biologics (ADMA) in Q3 2025: 4,256 shares worth $62.4K. The stake represents ﹤0.01% of the portfolio and ranks #341 among its holdings.

365 funds tracked by Wall St. Rank hold ADMA as of Q3 2025.

  • Point72 Europe held 4,256 shares of ADMA Biologics worth $62.4K as of Q3 2025.
  • ADMA Biologics was a new Point72 Europe position in Q3 2025.
  • ADMA Biologics made up ﹤0.01% of Point72 Europe's portfolio in Q3 2025, its #341 holding.
  • 365 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2025.

Based on Point72 Europe's 13F filing for Q3 2025, filed 14 Nov 2025.